Patent: 8,153,768
✉ Email this page to a colleague
Summary for Patent: 8,153,768
| Title: | Calicheamicin derivative-carrier conjugates |
| Abstract: | Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. |
| Inventor(s): | Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell |
| Assignee: | Wyeth Holdings LLC |
| Application Number: | US10/428,894 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: |
More… ↓ |
Details for Patent 8,153,768
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Wyeth Pharmaceuticals Llc | BESPONSA | inotuzumab ozogamicin | For Injection | 761040 | August 17, 2017 | ⤷ Start Trial | 2023-05-02 |
| Wyeth Pharmaceuticals Llc | MYLOTARG | gemtuzumab ozogamicin | For Injection | 761060 | September 01, 2017 | ⤷ Start Trial | 2023-05-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
